GLP-1 (Glucagon-Like Peptide-1): Research, Uses, Side Effects, and What It Means Now

GLP-1 is a natural hormone with broad effects on blood sugar, digestion, appetite, and more. In medicine, the term also refers to GLP-1 receptor agonists, a drug class built to mimic that hormone. These medicines are now used in type 2 diabetes and weight management, and the research base keeps expanding.

• GLP-1 helps regulate blood sugar, digestion, and appetite.
• GLP-1 receptor agonists are used in weekly or daily injections, depending on the drug and plan.
• Common side effects include nausea, stomach pain, and diarrhea.
• Current research also points to effects beyond weight and glucose, including heart, brain, and kidney-related pathways.

What GLP-1 Does in the Body

GLP-1 is a multifaceted hormone with broad pharmacological potential. A major review in PMC describes several core actions. GLP-1 stimulates insulin secretion in a glucose-dependent way. It also slows gastric emptying, reduces food intake, and increases natriuresis and diuresis. The same review also notes cardio- and neuroprotective effects, along with reduced inflammation and apoptosis.

That mix of effects helps explain why GLP-1 has drawn so much attention. It is not only about appetite. It also touches metabolism, the gut, and other systems. The review describes GLP-1 as a pleiotropic hormone, meaning it has many effects, not just one. That is a big reason it has moved from basic biology into active drug development.

UVA Health summarizes the same practical idea in simpler terms. GLP-1 mimics a natural hormone in the brain and gut that helps regulate blood sugar, digestion, and appetite. As appetite drops, people often feel full sooner. That can lead to lower calorie intake and weight loss. UVA Health also notes that many people on GLP-1 drugs take in 25% to 50% fewer calories daily, depending on the treatment plan and response.

Approved Medicines and Where They Fit

Several GLP-1 receptor agonists are already in clinical use. UVA Health lists common examples as semaglutide, tirzepatide, liraglutide, and dulaglutide, with brand names that include Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, Victoza, and Trulicity. The same source notes that these drugs come in different forms and doses, and treatment plans vary by person.

Hippo Education provides a current prescribing snapshot for 2025. It states that Ozempic (semaglutide injection) is approved for type 2 diabetes mellitus as an adjunct to diet and exercise, and also to reduce major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. It further notes a January 2025 approval to reduce the risk of chronic kidney disease progression and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.

Hippo Education also lists Rybelsus, the oral semaglutide product, as approved for type 2 diabetes and for reducing major adverse cardiovascular events in patients with type 2 diabetes at high risk for major adverse cardiovascular events. The same source says Mounjaro is approved for type 2 diabetes and that, at the time of its article, it had no current FDA indication for weight loss or cardiovascular disease prevention. Wegovy is described as approved for chronic weight management in adults with obesity and in certain adults with overweight.

Prime Therapeutics adds that the first GLP-1 receptor agonist for type 2 diabetes was FDA-approved 25 years ago, and that the first injectable GLP-1 for chronic weight management came more than a decade ago. It also states that newer obesity-related approvals have included secondary cardiovascular risk reduction, sleep apnea, and metabolic dysfunction-associated steatohepatitis, or MASH. According to that update, oral semaglutide became the first oral GLP-1 approved for weight loss and weight loss plus secondary cardiovascular risk reduction.

One practical point from UVA Health is that, to date, there are no generic versions of GLP-1 drugs. That matters because cost and insurance coverage can shape which drug a patient can realistically use.

What the Research Suggests Beyond Weight Loss

GLP-1 research is not limited to appetite and body weight. The review in PMC says GLP-1 has cardio- and neuroprotective effects, and it has implications for learning and memory, reward behavior, and palatability. It also points to possible roles in reducing inflammation and apoptosis.

Those findings matter because they suggest GLP-1 is more than a weight-loss signal. The review says GLP-1-based therapies have already become successful in type 2 diabetes, and that several GLP-1 therapies are being studied for obesity. It also says the hormone is an interesting candidate for therapies targeting obesity, diabetes, and neurodegenerative disorders.

Prime Therapeutics’ 2026 pipeline update shows how active the field remains. It says researchers are still learning about other possible uses for GLP-1, and that additional market growth is expected. The same update identifies three GLP-1 FDA decisions expected in early to mid-2026: a new Mounjaro indication to reduce the risk of major adverse cardiovascular events in patients with type 2 diabetes, Eli Lilly’s oral once-daily orforglipron for weight loss, and Novo Nordisk’s higher-dose 7.2 mg injectable once-weekly Wegovy for weight loss.

That pipeline snapshot does not mean those outcomes are final. It does show that GLP-1 research and development remain very active, with new questions around dose, route, and indication still being tested.

Side Effects and Tolerability

GLP-1 drugs can be useful, but they are not easy for everyone to tolerate. UVA Health says the more common side effects include nausea, belly pain, and diarrhea. GoodRx also lists nausea and vomiting, stomach pain, diarrhea, constipation, and appetite changes among the common side effects of GLP-1 medications.

UVA Health says the good news is that there are options for warding off or managing common complaints. Its article focuses on practical ways to tame side effects so people can stay on treatment longer and keep working toward their health goals. That framing is important. For many people, the question is not whether GLP-1 therapy can work, but whether side effects can be managed well enough to continue.

Because GLP-1 medicines affect metabolism, digestion, and appetite, side effects often show up in the same systems the drugs are meant to influence. That can make the early phase of treatment feel difficult. The research and clinical guidance in the provided sources point to a simple reality: benefit and discomfort can appear together.

Nutrition, Protein, and Muscle Preservation

One recurring concern in current GLP-1 discussions is what happens when appetite falls. Nutrishop’s GLP-1 Support Stack page argues that nutritional strategy becomes more important on GLP-1 therapy because reduced appetite can make it harder to eat enough protein each day. It also warns that some weight loss may come from muscle, not only fat. The page gives a target of 0.7 to 1 gram of protein per pound of body weight daily.

This is not a peer-reviewed guideline, so it should be read as product-focused advice rather than a universal standard. Still, it reflects a real clinical concern that appears often in GLP-1 conversations: when food intake drops, protein intake can drop too. That is especially relevant for people who are trying to lose weight without sacrificing strength, function, or recovery.

The same Nutrishop material emphasizes that proper nutrition and a solid exercise plan can help minimize muscle loss. It also says appetite suppression can make it difficult to ingest enough quality protein. In other words, the clinical story is not only about losing weight. It is also about what kind of weight is lost and how well the person can sustain the result.

For researchers and clinicians, this makes GLP-1 a more complex topic than a single appetite pathway. The treatment changes intake, but it may also change the composition of what is lost. That is one reason discussions around diet quality, resistance exercise, and recovery continue to follow GLP-1 therapy in practice.

Why the Field Still Matters

GLP-1 has moved from a basic hormone to a major therapeutic target. The PMC review describes a hormone with glucose-dependent insulin effects, slower gastric emptying, less food intake, and broader protective biology. UVA Health and Hippo Education show how that biology has been translated into real-world drugs for diabetes, weight management, and selected cardiovascular and kidney-related uses. Prime Therapeutics shows that the pipeline is still moving, with new approvals and new formulations under review.

At the same time, the practical side remains important. Common side effects are real. Insurance and cost can matter. Dosing, delivery, and approved use can differ from one product to another. Some products are weekly injections, some are daily injections, and one semaglutide form is oral. Those differences are not minor details. They shape who can use the drugs, how they are used, and how well people stay on them.

That is why GLP-1 research stays relevant across audiences. Researchers follow the biology. Biohackers watch the dosing and nutrition questions. Clinicians need the approved uses, side effect profile, and evolving pipeline. GLP-1 sits at the intersection of all three.

FAQ

What is GLP-1?

GLP-1 is a natural hormone that helps regulate blood sugar, digestion, and appetite. In medicine, GLP-1 receptor agonists are drugs designed to mimic that hormone.

What do GLP-1 drugs do?

According to the provided research, they stimulate glucose-dependent insulin secretion, slow gastric emptying, reduce food intake, and can increase natriuresis and diuresis. They are also linked with cardio- and neuroprotective effects in review literature.

What are the most common side effects?

Common side effects listed in the sources include nausea, vomiting, stomach pain, diarrhea, constipation, and appetite changes. UVA Health also highlights belly pain and digestive upset.

Which GLP-1 medicines are commonly used?

The sources name semaglutide, tirzepatide, liraglutide, and dulaglutide. Brand examples include Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, Victoza, Trulicity, and Rybelsus.

Why is GLP-1 still a major research topic?

Because its effects go beyond appetite and weight. Current research points to possible roles in glucose control, heart and kidney outcomes, brain-related effects, and new drug candidates still moving through the pipeline.